期刊
TRANSLATIONAL RESEARCH
卷 220, 期 -, 页码 57-67出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2020.03.006
关键词
-
资金
- Merck
- Nivalis
- Cubist
- Mead Johnson
- Rebiotix
- BioFire
- Assembly BioSciences
- NIAID [U01-AI124290]
- NIDDK [P30-DK56338]
Clostridioides difficile infection (CDI) is an urgent threat to global public health. Patient susceptibility to C. difficile is highly dependent on host immune status and gut dysbiosis resulting in loss of protective microbiota consortia that prevent spore germination, pathogen colonization, and disease pathogenesis. Recent clinical studies highlight the problems of differentiating symptomatic CDI from asymptomatic C. difficile carriage in patients with diarrhea. In this review, we consider how integration of microbiome and host immune systems biology data may aid in the clinical diagnosis of CDI when validated against gold standard testing and combined with standard microbiology laboratory assays.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据